Supplementary Table 4. Predictive capacity of the PCE-estimated 10-year ASCVD risk for incident diabetic nephropathy and retinopathy

Outcome	10-Year ASCVD risk category by PCE			10-Year ASCVD risk score by PCE, per 1% increment
	<7.5%	≥7.5% to <20%	≥20.0%	
DN				
GDES cohort				
Cases/Person-years	8/764	29/1,173	73/1,688	110/3,615
HR (95% CI)	1.00 (reference)	2.09 (0.95–4.62)	3.99 (1.90–8.36)	1.030 (1.021–1.040)
AUC (95% CI)	-	-	-	0.656 (0.602–0.710)
SDES cohort				
Cases/Person-years	5/434	13/567	43/1,214	61/2,225
HR (95% CI)	1.00 (reference)	1.86 (0.64–5.38)	3.38 (1.31–8.70)	1.020 (1.009–1.031)
AUC (95% CI)	-	-	-	0.622 (0.547–0.698)
Pooled				
Cases/Person-years	13/1,198	42/1,740	116/2,902	171/5,840
HR (95% CI)	1.00 (reference)	2.00 (1.06–3.78)	3.75 (2.09–6.71)	1.026 (1.019–1.033)
AUC (95% CI)	-	-	-	0.645 (0.603–0.691)
DR				
GDES cohort				
Cases/Person-years	58/543	89/830	130/1,216	277/2,599
HR (95% CI)	1.00 (reference)	1.01 (0.72–1.42)	0.92 (0.66–1.29)	0.997 (0.990–1.004)
AUC (95% CI)	-	-	-	0.504 (0.466–0.543)
SDES cohort				
Cases/Person-years	42/428	77/393	133/1,362	252/2,183
HR (95% CI)	1.00 (reference)	1.55 (1.05–2.28)	1.17 (0.82–1.69)	0.996 (0.990–1.002)
AUC (95% CI)	-	-	-	0.519 (0.482–0.556)
Pooled				
Cases/Person-years	100/980	166/1,223	263/2,578	529/4,782
HR (95% CI)	1.00 (reference)	1.22 (0.94–1.57)	1.03 (0.80–1.31)	0.996 (0.992–1.001)
AUC (95% CI)	-	-	-	0.512 (0.486–0.539)

Model adjusted for education level, regular drinking, duration of diabetes, use of insulin, and glycosylated hemoglobin. Cohort-specific results were pooled using inverse variance-weighted, fixed-effect meta-analyses. The 10-year ASCVD risk estimated by the PCE equations was categorised into low or borderline risk (<7.5%), intermediate risk (≥7.5% to <20%), and high risk (≥20.0%).

PCE, Pooled Cohort Equations; ASCVD, atherosclerotic cardiovascular disease; DN, diabetic nephropathy; GDES, Guangzhou Diabetic Eye Study; HR, hazard ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve; SDES, Shaoguan Diabetic Eye Study; DR, diabetic retinopathy.